


U.S.S.N. 09/445,865

Filed: February 11, 2000

AMENDMENT AND RESPONSE TO OFFICE ACTION

In the Claims

29. (Twice Amended) A method of treating a human patient with a target cell to be destroyed wherein the target cell expresses NQO2 the method comprising administering to the patient a prodrug which is converted to a cytotoxic drug by the action of NQO2 and an analogue of nicotinamide riboside (reduced) (NRH) [or an analogue thereof] having formula I:



which can pass reducing equivalents to NQO2, wherein the prodrug is CB-1954, and wherein R¹ is selected from the group consisting of: substituted alkyl, including substitution by CONH₂, OH, halogen, CN and COOH; alkyl, aryl, substituted aryl; CONR^aR^b, where R^a and R^b are independently H, alkyl, or substituted alkyl, and R² and R³ are independently H, alkyl, or substituted alkyl and R⁴ is any of H, alkyl, substituted alkyl, halogen, CN, COOH, CONH₂, or OH.

33. (Twice Amended) The method of claim 29, the method further comprising determining, before administering the prodrug [or] and [NRH or an] analogue [thereof] of NRH, whether the target cell to be treated expresses NQO2.

564397v1


ERD 100
078230/00004

U.S.S.N. 09/445,865

Filed: February 11, 2000

AMENDMENT AND RESPONSE TO OFFICE ACTION

42. (New) The method of claim 29, wherein the analogue of NRH has formula II:



wherein R is selected from the group consisting of: substituted-alkyl, including substitution by CONH₂, OH, halogen, CN and COOH; and alkyl.

43. (New) The method of claim 29 wherein the alkyl group is C₁ to C₆ alkyl.

44. (New) The method of claim 42 wherein R is selected from the group consisting of: -CH₂CONH₂; -CH₂CH₂CH₂SO₃; -CH₂CH₂CH₃; -CH(CH₃)₂; -CH₂CH₂CH₂OH; -CH₂CH₂OH; CH₂CH₂COOH; -CH₂C₆H₅; -CH₃; -CH₂CH₃; -CH₂CH₂C₆H₅.